Early-stage lung cancer findings end a debate, put focus on next steps.
McNeil
Caroline
C
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002170:Canada; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data*; D002945:Cisplatin / Q000008:administration & dosage; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018579:Patient Selection; D011799:Quinazolines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D015983:Selection Bias; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011799:Quinazolines; D000068258:Bevacizumab; D014747:Vinblastine; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D002945:Cisplatin; D000077235:Vinorelbine; D000077156:Gefitinib